Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Ovarian Brenner Tumor
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Undifferentiated Fallopian Tube Carcinoma
- Undifferentiated Ovarian Carcinoma
Interventions
- DRUG: Bortezomib
- DRUG: Carboplatin
- OTHER: Laboratory Biomarker Analysis
- OTHER: Pharmacological Study
Sponsor
National Cancer Institute (NCI)
Collaborators